July 2022 in “International Journal of Trichology” Tofacitinib helped an 8-year-old child recover from a type of hair loss that is hard to treat.
October 2024 in “Journal of Pakistan Association of Dermatologists” Tofacitinib helped a 21-year-old regrow hair after alopecia totalis.
1 citations
,
January 2024 in “Arab Board Medical Journal” Tofacitinib effectively regrows hair in alopecia areata patients, especially in younger individuals, with manageable side effects.
September 2025 in “Annals of African Medicine”
9 citations
,
October 2019 in “Dermatologic Therapy” Oral tofacitinib has a moderate success rate and is generally safe for treating hair loss in some patients.
Isotretinoin reduced inflammation in tufted hair folliculitis, but hair tufting remained.
November 2020 in “Dubai medical journal” Tofacitinib may effectively regrow hair in alopecia totalis patients.
The research developed new fortilin protein constructs for potential heart disease treatments.
May 2025 in “Journal of Pharmacy And Bioallied Sciences” Tofacitinib effectively promotes hair regrowth in children with alopecia areata, but more research on long-term safety is needed.
October 2023 in “Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy” New, eco-friendly methods accurately measure TDF and FNS in a new urologic medication.
23 citations
,
January 2016 in “Frontiers in immunology” Using low-dose IL-2 to increase regulatory T cells might be a safe way to treat type 1 diabetes without severe side effects.
17 citations
,
January 2019 in “Dermatologic Therapy” Tofacitinib is effective and safe for long-term treatment of severe alopecia areata, with many patients achieving complete hair regrowth.
January 2018 in “International journal of medical biochemistry” Women with telogen effluvium have lower levels of iron, folate, and vitamin B12.
24 citations
,
August 2019 in “Journal of the American Academy of Dermatology” Teledermatology reduces unnecessary in-person visits and improves care.
4 citations
,
November 2020 in “Acta Dermato Venereologica” Tofacitinib effectively improved severe skin symptoms in a patient with Hypohidrotic Ectodermal Dysplasia.
49 citations
,
May 2018 in “Journal of the American Academy of Dermatology” Applying 2% tofacitinib cream helped some children with severe hair loss grow back hair.
1 citations
,
January 2024 in “Pharmaceuticals” A new carrier improves skin delivery of tofacitinib for treating inflammatory skin diseases.
September 2022 in “PubMed” Entadfi, a mix of finasteride and tadalafil, is used for BPH.
December 2024 in “Medical alphabet” Understanding and addressing the causes of telogen effluvium is crucial for effective treatment.
Oral tofacitinib effectively treats alopecia areata long-term with manageable side effects.
July 2018 in “Elsevier eBooks” Telogen Effluvium is a common, usually reversible hair loss condition, often improved by removing the trigger and possibly treated with various products, though their effectiveness is uncertain.
March 2015 in “CRC Press eBooks” Telogen effluvium is a type of hair loss in women caused by many factors, and iron and thyroid tests are recommended for diagnosis.
32 citations
,
April 2006 in “The Journal of Urology” Using finasteride with TIP extends time off period for prostate cancer patients.
145 citations
,
May 2008 in “Cancer Science” Cancer cells often have more copies of TERT and TERC genes, which helps them grow and could affect patient outcomes.
January 2013 in “edoc (University of Basel)” TRF1 is crucial for creating and maintaining stem cells and marks both pluripotent and adult stem cells.
January 2025 in “International Journal of Dermatology Venereology and Leprosy Sciences” Tofacitinib improved hair regrowth and quality of life in children with alopecia areata, with mild side effects.
Tofacitinib significantly improved symptoms in a patient with overlapping autoimmune disorders.
January 2024 in “Dermatologic therapy” Tofacitinib is a safe treatment for hair loss in children, but long-term use may be needed for best results.
5 citations
,
August 2018 in “PubMed” An 8-year-old with severe hair loss regrew all hair after six months of tofacitinib treatment.
Telogen effluvium causes temporary hair loss, especially in women.